2023-03-08 15:23:13 ET
- BioCryst Pharmaceuticals ( NASDAQ: BCRX ) announced Wednesday that an expert panel in Canada recommended its hereditary angioedema (HAE) therapy Orladeyo (berotralstat) for reimbursement.
- According to the company, the Canadian Drug Expert Committee (CDEC) of the Canadian Agency for Drugs and Technologies in Health (CADTH) has endorsed Orladeyo to be reimbursed when used for routine prevention of HAE attacks in those aged 12 years and above.
- “Today’s announcement is a welcome one for the HAE community in Canada, as it should help increase access to this oral prophylactic treatment across our country,” said Daphne Dumbrille, a representative of HAE Canada.
- In June 2022, Canada authorized Orladeyo, an oral, once-daily therapy for the routine prevention of HAE attacks in people aged 12 years and above.
- With a strong cash balance, BioCryst ( BCRX ) stands out as “an ideal buyout candidate because of its uncomplicated business profile,” Seeking Alpha contributor Avisol Capital Partners argued on Wednesday.
For further details see:
BioCryst wins Canadian nod for Orladeyo reimbursement